S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.02%) 40 134 points
Nasdaq Futures
(-0.12%) 18 481 points
Oil
(0.75%) $81.96
Gas
(-1.75%) $1.688
Gold
(0.25%) $2 218.30
Silver
(-0.69%) $24.58
Platinum
(-0.04%) $909.35
USD/EUR
(0.46%) $0.928
USD/NOK
(0.69%) $10.84
USD/GBP
(0.27%) $0.793
USD/RUB
(-0.15%) $92.31

Realtime updates for 4D Molecular [FDMT]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
71.43%
return 2.64%
SELL
50.00%
return 7.65%
Last Updated27 Mar 2024 @ 16:00

5.35% $ 35.87

SELL 61318 min ago

@ $27.97

Issued: 14 Feb 2024 @ 15:13


Return: 28.24%


Previous signal: Feb 14 - 13:43


Previous signal: Buy


Return: 2.04 %

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology...

Stats
Today's Volume 716 828
Average Volume 1.14M
Market Cap 1.79B
EPS $0 ( 2024-03-20 )
Next earnings date ( $-0.710 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -13.90
ATR14 $0.0630 (0.18%)
Insider Trading
Date Person Action Amount type
2024-03-18 Bizily Scott Sell 1 250 Stock Option (Right To Buy)
2024-03-18 Bizily Scott Sell 500 Stock Option (Right To Buy)
2024-03-18 Bizily Scott Buy 1 250 Common Stock
2024-03-18 Bizily Scott Buy 500 Common Stock
2024-03-18 Bizily Scott Sell 1 750 Common Stock
INSIDER POWER
30.86
Last 99 transactions
Buy: 3 613 912 | Sell: 1 900 452

Volume Correlation

Long: 0.41 (neutral)
Short: 0.18 (neutral)
Signal:(62.712) Neutral

4D Molecular Correlation

10 Most Positive Correlations
AFYA0.848
RMCF0.839
GOEV0.826
NTCT0.826
SLM0.821
IMGN0.818
TRMK0.817
NDAQ0.817
PRCT0.816
LSXMA0.816
10 Most Negative Correlations
ISDX-0.838
ZIONP-0.827
TRHC-0.826
NVSAU-0.823
KSICU-0.822
IOAC-0.821
GRBK-0.815
XFIN-0.813
VRIG-0.812
BRIVU-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

4D Molecular Correlation - Currency/Commodity

The country flag -0.03
( neutral )
The country flag -0.26
( neutral )
The country flag 0.00
( neutral )
The country flag -0.06
( neutral )
The country flag 0.63
( weak )
The country flag 0.65
( weak )

4D Molecular Financials

Annual 2023
Revenue: $20.72M
Gross Profit: $14.97M (72.26 %)
EPS: $-2.58
Q4 2023
Revenue: $-19 000.00
Gross Profit: $-4.26M (22 394.74 %)
EPS: $-0.000800
Q3 2023
Revenue: $20.20M
Gross Profit: $18.81M (93.09 %)
EPS: $-0.240
Q2 2023
Revenue: $239 000
Gross Profit: $-1.19M (-497.49 %)
EPS: $-0.770

Financial Reports:

No articles found.

4D Molecular

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators